First drug to slow Alzheimer’s progression approved in US

Current Affairs Top Stories

US officials have indeed granted full approval to the Alzheimer’s drug Leqembi (also known as Aduhelm), it represents a significant development in the field of Alzheimer’s treatment.

courtesy by usnews.com

Aduhelm is an amyloid-beta-directed antibody designed to reduce amyloid plaque in the brain, which is a hallmark characteristic of Alzheimer’s disease. Clinical trials have shown that Aduhelm can slow the cognitive decline associated with Alzheimer’s disease.

The approval of Aduhelm could potentially provide a new treatment option for individuals with Alzheimer’s and their caregivers. It’s important to note that the approval and use of Aduhelm may still be subject to specific guidelines and considerations, and healthcare professionals will play a crucial role in determining its appropriate use.

Leave a Reply

Your email address will not be published. Required fields are marked *